이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Identifying Multidimensional Signatures of Gastric Interoception in Functional Dyspepsia (IMAGINE)

2026년 8월 14일 업데이트: Helen Burton-Murray, PHD, Massachusetts General Hospital
This study is being conducted to investigate gut-brain communication in individuals with functional dyspepsia and anorexia nervosa. The hope is that what the investigators learn from this study will improve the understanding the conditions better to improve treatments.

연구 개요

연구 유형

중재적

등록 (추정된)

150

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Massachusetts
      • Boston, Massachusetts, 미국, 02114
        • 모병
        • Massachusetts General Hospital
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

설명

Participant Inclusion Criteria--

Functional Dyspepsia Group:

  • Males and females; ages 18-65 years
  • Rome V functional dyspepsia post-prandial distress syndrome subtype
  • Negative upper endoscopy or upper GI series to rule out structural/organic cause for FD
  • greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
  • Fluent in English
  • Willing and able to provide informed consent
  • Stable dose for 30 days prior to Visit 1 if on a neuropsychiatric medication (e.g., TCA, SNRI, SSRI mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)
  • No current plans to initiate a new or change dosing on a neuropsychiatric medication within the study period

Anorexia Nervosa Group:

  • Males and females; ages 18-65 years
  • DSM-5 anorexia restricting-type by the Eating Disorder Module in the Diagnostic Interview for Mood, Anxiety, and OCD and related Neuropsychiatric Disorders (DIAMOND)
  • greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
  • Fluent in English
  • Willing and able to provide informed consent
  • Stable dose for 30 days prior to Visit 1 if on an SSRI
  • No current plans to initiate a new neuromodulator
  • No current plans to initiate a new SSRI or change dosing on an SSRI

Healthy Controls:

  • Males and females; ages 18-65 years
  • BMI greater than or equal to 18.5 kg/m2
  • Fluent in English
  • Willing and able to provide informed consent

Participant Exclusion Criteria--

Functional Dyspepsia Group:

  • Presence of other conditions that could explain the patient's symptoms by medical chart:

    • Pyloric or intestinal obstruction (by EGD, UGI, or Abdominal CT)
    • Active H.pylori (by CLO test or stool antigen test)
    • Active inflammatory bowel disease
    • Eosinophilic gastroenteritis or eosinophilic esophagitis
    • Acute renal failure
    • Chronic renal failure (serum creatinine >3 mg/dL) and/or on hemodialysis or peritoneal dialysis
    • Acute liver failure
    • Any acute gastrointestinal process
    • Any plausible structural or metabolic causes
    • Heartburn as predominant symptom
    • History of peptic ulcer
  • Symptom resolution with antisecretory therapy (PPI use for other reasons that did not resolve FD symptoms will be allowed)
  • Endorses any contraindications to MRI
  • Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
  • Allergy to pineapple (used in the test meal during MRI)
  • History of GI tract surgery or any serious medical condition (e.g., cancer)
  • Pregnancy/breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
  • Narcotic analgesics greater than three days per week
  • Cannabinoid use greater than three days per week
  • Intellectual disability by history
  • Illiteracy
  • History of weight/shape-based eating disorder including anorexia nervosa by DIAMOND
  • Current binge eating by DIAMOND
  • Current self-induced vomiting by DIAMOND
  • Current laxative or diuretic misuse by DIAMOND
  • Current substance/alcohol use disorder within past year by DIAMOND
  • Current/history of psychosis by DIAMOND
  • Current mania by DIAMOND
  • Active suicidal ideation by modified DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
  • Inability or unwillingness to consume food by mouth
  • Inability to provide informed consent

Anorexia Nervosa Group:

  • Diagnosis of chronic gastrointestinal disorder
  • Rome V functional dyspepsia
  • Endorses any contraindications to MRI
  • Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
  • Allergy to pineapple (used in the test meal during MRI)
  • History of GI tract surgery or any serious medical condition (e.g., cancer)
  • Pregnancy/breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
  • Narcotic analgesics greater than three days per week
  • Cannabinoid use greater than three days per week
  • Intellectual disability by history
  • Illiteracy
  • Current binge eating by DIAMOND
  • Current self-induced vomiting by DIAMOND
  • Current laxative or diuretic misuse by DIAMOND
  • Current substance/alcohol use disorder within past year by DIAMOND
  • Current/history of psychosis by DIAMOND
  • Current mania by DIAMOND
  • Active suicidal ideation by DIAMOND abbreviated suicide module; passive suicidal ideation is allowed
  • Inability or unwillingness to consume food by mouth
  • Inability to provide informed consent
  • Current use of neuropsychiatric medication other than an SSRI (e.g., TCA, SNRI, mirtazapine, atypical antipsychotic, gabapentin, buspirone, pregabalin)

Healthy Controls:

  • Diagnosis of chronic gastrointestinal or pain disorder
  • Rome V functional dyspepsia
  • greater than or equal to 5.5 gut interoceptive awareness score (by VSI awareness subscale)
  • Current use of a medication known to influence gastric sensorimotor functions (including neuromodulators and SSRIs)
  • Active psychiatric disorder including a feeding/eating disorder by DIAMOND
  • Endorses any contraindications to MRI
  • Body weight of 450 lbs or greater or BMI of 50 kg/m2 or greater (limit of MRI table)
  • Allergy to pineapple (used in the test meal during MRI)
  • History of GI tract surgery or any serious medical condition (e.g., cancer)
  • Pregnancy/breastfeeding within the last 8 weeks
  • Uncontrolled diabetes (indicated by HbA1c greater than or equal to 7%) by chart
  • Narcotic analgesics greater than three days per week
  • Cannabinoid use greater than three days per week
  • Intellectual disability by history
  • Illiteracy
  • Current binge eating by DIAMOND
  • Current self-induced vomiting by DIAMOND
  • Current laxative or diuretic misuse by DIAMOND
  • Current substance/alcohol use disorder within past year by DIAMOND
  • Current/history of psychosis by DIAMOND
  • Current mania by DIAMOND
  • Active suicidal ideation by DIAMOND modified suicide module; passive suicidal ideation is allowed
  • Inability or unwillingness to consume food by mouth
  • Inability to provide informed consent

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 기초 과학
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
다른: Functional Dyspepsia, Healthy Control, Anorexia Nervosa
Pineapple pudding snack, with pre- and post-snack fMRI

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Visual interoception task
기간: Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
The study team will be investigating brain activity and connectivity during an interoception task. This will be measured via functional magnetic resonance imaging (fMRI) which is able to measure blood flow to regions of the brain.
Day 1, visit 1, 30-minute scan and visit 2 (within approximately two weeks of day 1), 30-minute scan
Resting state connectivity
기간: Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
Change in brain activity during rest pre and post prandially using functional magnetic resonance imaging (fMRI).
Visit 2 (second visit, within approximately 2 weeks of day 1 of the study), 60 minute scan.
Gastric peristaltic velocity
기간: 30 minutes (only in Visit 2, within approximately two weeks of Visit 1)
MRI-derived gastric motility outcome
30 minutes (only in Visit 2, within approximately two weeks of Visit 1)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Helen Burton-Murray, PhD, Massachusetts General Hospital

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 16일

기본 완료 (추정된)

2030년 3월 1일

연구 완료 (추정된)

2031년 3월 1일

연구 등록 날짜

최초 제출

2026년 6월 29일

QC 기준을 충족하는 최초 제출

2026년 8월 14일

처음 게시됨 (실제)

2026년 8월 19일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 8월 14일

마지막으로 확인됨

2026년 8월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • 2025P001856
  • R01DK145599 (미국 NIH 보조금/계약)

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다